✦ LIBER ✦

Phase II trial of indicine N-oxide in relapsed pediatric solid tumors

✍ Scribed by James S. Miser; William A. Smithson; William Krivit; Carla Hughes; Dianne Davis; Mark Krailo; Denman Hammond

Publisher: Springer US
Year: 1991
Tongue: English
Weight: 280 KB
Volume: 9
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00183576

No coin nor oath required. For personal study only.

✦ Synopsis

We used indicine N-oxide to treat 46 children with malignant solid tumors: 17 with osteosarcoma, 12 with neuroblastoma, 13 with a brain tumor, and 4 with other miscellaneous tumors. The efficacy and toxicity of the drug was assessed at the dose of 2000 mg/m2/day for five consecutive days. None of the 39 patients evaluable for response achieved a complete or partial response. Hepatotoxicity was experienced by 13 patients: 11 patients developed asymptomatic elevations of transaminases, 1 patient developed hyperbilirubinemia, and 1 developed ascites. Indicine N-oxide appears to be ineffective in the treatment of osteosarcoma, neuroblastoma, and pediatric brain tumors at this dose and schedule. Because higher doses are associated with an unacceptably high incidence of severe, irreversible hepatotoxicity, we do not recommend further study of this agent in pediatric solid tumors.

📜 SIMILAR VOLUMES

A phase I trial of fazarabine in refract

A phase I trial of fazarabine in refractory pediatric solid tumors

✍ Mark L. Bernstein; V. Michael Whitehead; Holcombe Grier; Ron Dubowy; Vita Land; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 289 KB

Phase I trial of trimetrexate in pediatr

Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study

✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma

A phase-II clinical trial of 4′-epi-doxo

A phase-II clinical trial of 4′-epi-doxorubicin in advanced solid tumors

✍ Andrea Martoni; Michele Giovannini; Luciana Tomasi; Carlo Maurizio Camaggi; Bart 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 357 KB

Phase II trial of ICRF-187 in children w

Phase II trial of ICRF-187 in children with solid tumors and acute leukemia

✍ Tribhawan Vats; Barton Kamen; Jeffrey P. Krischer 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 280 KB

ICRF-187 is the ( + ) enantiomer of the racemic mixture razoxane . This compound is much more water soluble and thus could be formulated for parental use. The maximum tolerated dose in children after phase I trials was determined to be 3500 mg/MVday x 3 days. A phase II trial of ICRF-187 was done in

A Phase II trial of the oral mTOR inhibi

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

✍ Patrick B. Johnston; David J. Inwards; Joseph P. Colgan; Betsy R. Laplant; Brian 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB

Ifosfamide/etoposide combination in the

Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study

✍ Faith H. Kung; Charles B. Pratt; Roger A. Vega; Norman Jaffe; Douglas Strother; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 509 KB

Background. The prognosis for children with recurrent or resistant malignant solid tumors remains dismal. More effective rescue therapy is needed for these children. Methods. Between August 1987 and November 1990, 311 children with recurrent or resistant malignant solid tumors were treated by inves